Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer

Histopathology

Volumn 57, Issue 4, 2010, Pages 572-579

  Barbisan, Francesca ^a   Mazzucchelli, Roberta ^a   Santinelli, Alfredo ^a   Scarpelli, Marina ^a   Lopez Beltran, Antonio ^b   Cheng, Liang ^c   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrophy; Cystoprostatectomy; High grade prostatic intraepithelial neoplasia; Prostate cancer; Prostate stem cell antigen; Prostatic carcinogenesis

Indexed keywords

KI 67 ANTIGEN; PROSTATE STEM CELL ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTECTOMY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE ATROPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RADICAL RETROPUBIC PROSTATECTOMY;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CELL TRANSFORMATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650430267     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03666.x     Document Type: Article

References (33)

1. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol. Endocrinol. 2002; 16; 2323-2337.
2. Gu Z, Thomas G, Yamashiro J et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19; 1288-1296.
3. Han KR, Seligson DB, Liu X et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J. Urol. 2004; 171; 1117-1121.
4. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 1998; 95; 1735-1740.
5. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008; 68; 861-869.
6. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr. Opin. Urol. 2002; 12; 401-406.
7. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 2009; 277; 126-132.
8. Lam JS, Yamashiro J, Shintaku IP et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 2005; 11; 2591-2596.
9. Zhigang Z, Wenlu S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J. Surg. Oncol. 2004; 2; 13.
10. Zhigang Z, Wenlu S. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005; 65; 299-305.
11. Zhigang Z, Wenlu S. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer. Prostate 2007; 67; 1143-1151.
12. Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int. J. Cancer 2008; 122; 864-870.
13. Zhigang Z, Wenlu S. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate. Prostate 2008; 6; 190-199.
14. Mazzucchelli R, Barbisan F, Santinelli A et al. Immunohistochemical expression of prostate stem cell antigen (PSCA) in cystoprostatectomies with incidental prostate cancer. Int. J. Immunopathol. Pharmacol. 2009; 22; 755-762.
15. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal. Quant. Cytol. Histol. 2008; 30; 190-198.
16. Egevad L. Recent trends in Gleason grading of prostate cancer. II. Prognosis, reproducibility and reporting. Anal. Quant. Cytol. Histol. 2008; 30; 254-260.
17. Helpap B, Egevad L. Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. Anal. Quant. Cytol. Histol. 2008; 30; 1-7.
18. Santinelli A, Mazzucchelli R, Barbisan F et al. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am. J. Clin. Pathol. 2007; 128; 657-666.
19. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol. Cancer Res. 2002; 1; 113-121.
20. Reiter RE, Sato I, Thomas G et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000; 27; 95-103.
21. Watabe T, Lin M, Ide H et al. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc. Natl Acad. Sci. USA 2002; 99; 401-406.
22. Bahrenberg G, Brauers A, Joost HG, Jakse G. PSCA expression is regulated by phorbol ester and cell adhesion in the bladder carcinoma cell line RT112. Cancer Lett. 2001; 168; 37-43.
23. Bamezai A, Rock KL. Overexpressed Ly-6A.2 mediates cell-cell adhesion by binding a ligand expressed on lymphoid cells. Proc. Natl Acad. Sci. USA 1995; 92; 4294-4298.
24. Brakenhoff RH, Gerretsen M, Knippels EM et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J. Cell Biol. 1995; 129; 1677-1689.
25. Katz BZ, Eshel R, Sagi-Assif O, Witz IP. An association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype. Int. J. Cancer 1994; 59; 684-691.
26. Noda S, Kosugi A, Saitoh S, Narumiya S, Hamaoka T. Protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal through thymic shared antigen-1/stem cell antigen-2. J. Exp. Med. 1996; 183; 2355-2360.
27. Thomas PM, Samelson LE. The glycophosphatidylinositol-anchored Thy-1 molecule interacts with the p60fyn protein tyrosine kinase in T cells. J. Biol. Chem. 1992; 267; 12317-12322.
28. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997; 57; 524-531.
29. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 1998; 153; 141-148.
30. Sato K, Qian J, Slezak JM et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl Cancer Inst. 1999; 91; 1574-1580.
31. Van Den Berg C, Guan XY, Von Hoff D et al. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin. Cancer Res. 1995; 1; 11-18.
32. Visakorpi T, Kallioniemi AH, Syvänen AC et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 1995; 55; 342-347.
33. Barbisan F, Mazzucchelli R, Santinelli A et al. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur. Urol. 2009; 56; 105-112.